Surgical management of the axilla and adjuvant systemic therapy strategies have evolved considerably.  A recent survey revealed substantial variation in surgeon management suggesting the potential for overtreatment of many patients and the need for education in this area.

The endocrine therapy options are expanding for patients with early stage and advanced stage disease.

The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

Locoregional management strategies have considerably evolved.  Although several randomized studies have identified patients that do not need ALND, a recent survey revealed substantial variation in surgeon management suggesting the potential for overtreatment of many patients and the need for educ

With the release of the 8th edition of the AJCC staging manual,  it is important for clinicians to be aware of the updates to the AJCC TNM staging in order to select appropriate treatment, evaluate treatment outcomes, participate in clinical trials, and facilitate accurate information sharing amo

Individuals found to have a hereditary breast cancer syndrome should be managed appropriately, with an emphasis on screening considerably earlier than standard recommendations.